Valuation: ZIM Laboratories Limited

Market Cap 6.72B 69.76M 60.96M 56.25M 51.85M 97.73M 99.9M 672M 264M 3.29B 262M 256M 11.33B P/E 2025
32.1x
P/E 2026 50.3x
Enterprise Value 7.58B 78.72M 68.79M 63.48M 58.51M 110M 113M 759M 298M 3.71B 296M 289M 12.78B EV / Sales 2025
1.34x
EV / Sales 2026 1.09x
Free-Float
28.79%
Yield 2025 *
-
Yield 2026 -
1 day+1.95%
1 week+10.29%
Current month+0.93%
1 month+10.04%
3 months+57.36%
6 months+58.02%
Current year+74.50%
1 week 111.5
Extreme 111.5
125.5
1 month 111.5
Extreme 111.5
133.95
Current year 59.72
Extreme 59.72
133.95
1 year 59.72
Extreme 59.72
133.95
3 years 59.72
Extreme 59.72
151.75
5 years 36.37
Extreme 36.3667
151.75
10 years 14
Extreme 14
151.75
Manager TitleAgeSince
Chief Executive Officer - 2001-12-31
Director of Finance/CFO - 2019-03-31
Director of Finance/CFO - 1990-12-31
Director TitleAgeSince
Chairman - 1989-12-31
Director/Board Member - 1990-12-31
Director/Board Member - 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.95%+10.29%+5.51%+2.20% 69.76M
-0.90%-0.15%+14.11%+81.10% 48.15B
-0.23%-1.65%+67.15%+112.03% 35.59B
-0.76%-1.44%-4.29%+37.63% 11.9B
-0.88%-0.62%+17.31%+89.97% 11.85B
+0.19%+2.87%+34.92%+139.73% 9.31B
+3.37%-0.10%+51.64%-3.75% 7.02B
-0.75%-0.91%+17.45%+37.70% 6.91B
-2.25%-2.08%+0.45%+209.99% 6.55B
-9.93%+0.35%-31.51%+16.58% 6.13B
Average -1.02%+1.09%+17.27%+72.32% 14.35B
Weighted average by Cap. -0.88%-0.42%+26.78%+86.55%

Financials

2025 2026
Net sales 3.79B 39.37M 34.4M 31.75M 29.26M 55.16M 56.38M 379M 149M 1.86B 148M 145M 6.39B 3.74B 38.88M 33.98M 31.35M 28.9M 54.47M 55.68M 375M 147M 1.83B 146M 143M 6.31B
Net income 122M 1.26M 1.1M 1.02M 939K 1.77M 1.81M 12.18M 4.79M 59.58M 4.74M 4.64M 205M 58.38M 606K 530K 489K 451K 849K 868K 5.84M 2.3M 28.59M 2.28M 2.23M 98.43M
Net Debt 1.16B 12.02M 10.51M 9.69M 8.94M 16.84M 17.22M 116M 45.57M 567M 45.14M 44.15M 1.95B 863M 8.96M 7.83M 7.23M 6.66M 12.56M 12.83M 86.38M 33.98M 423M 33.66M 32.92M 1.46B
Logo ZIM Laboratories Limited
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Employees
632
Date Price Change Volume
26-07-17 ₹125.45 +1.95% 8,530
26-07-16 ₹123.05 +1.99% 3,069
26-07-15 ₹120.65 +1.99% 5,681
26-07-14 ₹118.30 +1.98% 2,646
26-07-13 ₹116.00 +1.98% 3,031
  1. Stock Market
  2. Stocks
  3. ZIMLAB Stock